Marco Ventin MD

General Surgery @UCIrvineSurgery | Postdoc @CedarsSinai @MGHSurgery Ferrone Lab | Interested in CGSO, HPB Surgery, Cancer Immunology & Immunotherapy

[Marco Ventin MD @MVentinMD]

Beyond excited to see our work in @JAMASurgery

We developed a risk score for recurrence and survival in LN–negative PanNETs, identifying patients at low, moderate, and high risk to guide risk-adapted postoperative surveillance and management. #PANDA

https://t.co/pMyOABWSf7

[Marco Ventin MD @MVentinMD]

Exciting to see our manuscript out @JournalofExper1 B7-H3 CAR T cells eradicate intrahepatic cholangiocarcinoma and induce durable response in preclinical models. @MGHSurgery @CedarsSinaiMed @curecc https://t.co/gwHX0VQPTC

[Marco Ventin MD @MVentinMD]

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer | New England Journal of Medicine https://t.co/cTFKNMXhqR

[Annals of Surgery @AnnalsofSurgery]

Drain fluid amylase levels on postoperative days 1 and 3 accurately estimated the risk of clinically relevant postoperative pancreatic fistula after pancreatoduodenectomy. https://t.co/qHlU55qhU8

[Julie Hallet @HalletJulie]

When do you operate on a PanNET?
A tough and nuanced call 😳

🦓 Unpacking that with @EAHPBA x @SocSurgOnc x @NANETS1 with @spartelli @decsamethasone @valentinandreas

📝 We will be drawing from recent @BJSurgery NETs commission paper

⏰May 21, 18:00 CEST - 🆓 registration 👇🏻

[Marco Ventin MD @MVentinMD]

Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma | ⁦@NEJMClinician⁩ https://t.co/VwxopRaRGm

[Marco Ventin MD @MVentinMD]

A very high yield read - Surgical management of pancreatic neuroendocrine tumours | BJS | Oxford Academic ⁦@BJSurgery⁩ ⁦@HalletJulie⁩ https://t.co/sR80BYrhS8

[Syed A. Ahmad @SyedAAhmad5]

MARGINS SHOULD NOT AFFECT SURVIVAL IN SYSTEMIC CANCERS LIKE PDAC. Margins can be reflective of biology, similar to positive LNs. After neoadjuvant tx bad biology progress so for those getting tonsurgery margin loses its significance.

[Marco Ventin MD @MVentinMD]

Clonal evolutionary analysis reveals patterns of malignant transformation of Intraductal Papillary Mucinous Neoplasms of the pancreas | Nature Communications ⁩ https://t.co/rGFGdNqZwi

[Marco Ventin MD @MVentinMD]

Honored to present our @JAMASurgery research today at the #SSO2026! Grateful to all the mentors and the scientific committee for this podium. Great HPB debates! @UCIrvineSurgery

[Marco Ventin MD @MVentinMD]

Development and Prospective Validation of a Cell-free DNA–Based Model for the Early Detection of Pancreatic Cancer | Cancer Discovery | American Association for Cancer Research https://t.co/gUqYYxUkNQ

[Marco Ventin MD @MVentinMD]

Check out ⁦@AnnSurgOncol⁩ Implications of Homologous Recombination Deficiency for Neoadjuvant Platinum-Based Chemotherapy in Pancreatic Cancer https://t.co/VbQkTIoukk

[Giovanni Marchegiani @Gio_Marchegiani]

🔵 Post pancreatectomy mortality: the new seminal paper from @ISGPS_news @AnnalsofSurgery

👉 occurring within 90 days from pancreatectomy linked to it through root-cause analysis

3️⃣ categories ✂️ vascular complexity 💦 pancreas specific 🫀 C/P sudden

https://t.co/dxlWbiiaQq

[JAMA Surgery @JAMASurgery]

Among patients with unexplained acute recurrent #pancreatitis and pancreas divisum, endoscopic retrograde cholangiopancreatography (ERCP) with minor papillotomy does not reduce the risk of another episode of acute pancreatitis or related sequelae.

https://t.co/ZloBDyYsu0

[Anish Jay Jain MD @AnishJayJain]

Insightful Thread from Dr. @PatricioPolanc0 on IPMNs and prognostic utility of NGS

Great read for all lovers of the pancreas and trainees @MVentinMD @CarstenT94 @AndrewFlemingMD @med_trisha @SchultzKurt @FemiSuraju

Great articles from @GilbertZMurimwa & @amudhan_kannan!!

[Marco Ventin MD @MVentinMD]

Our new study unveils the association and underlying mechanisms between high spicy diet consumption / capsaicin-induced chronic gut inflammation and idiopathic short stature. @NatureComms
Happy New Year!

https://t.co/BstpDDwfvE

[STITCHES - the Best Papers in General Surgery @stitchestoday]

Predicting Recurrence in Lymph Node-Negative Pancreatic Tumors

by Ventin M, Arya S (...) Ferrone CR et 15 al. in JAMA Surg

🪡 read our summary 👉 https://t.co/JTk6e6AuNl
📖 read the article: https://t.co/ikAi4TMtVm

[Annals of Surgery @AnnalsofSurgery]

Among patients with PDAC undergoing postneoadjuvant pancreatoduodenectomy, revision of pancreatic neck margin did not improve outcomes compared to incomplete resection. https://t.co/ruPzR1UiBI

[Anish Jay Jain MD @AnishJayJain]

Grateful to @timnewhook19 & @VautheyMD for their guidance throughout this project!

Huge thanks also to my friends & colleagues @mateolendoire @Haddad_Antony for their help!

Treating obstructive jaundice
➕minimizing cholangitis ➕ adequate sFLR 🟰 safe resection of pCCA

[STITCHES - the Best Papers in General Surgery @stitchestoday]

Spleen-Saving Techniques in Distal Pancreatectomy: Key Findings

by Arya S, Ventin M (...) Ferrone CR et 9 al. in Ann Surg

🪡 read our summary 👉 https://t.co/Xd9beSaXVD
📖 read the article: https://t.co/zZciT8tNvi

[Thor Halfdanarson @OncoThor]

Clinically useful papers to help predict outcomes following curative intent resection of NETs are extremely helpful for clinicians counseling patients. This is one such paper you should read if you take care of patients with pancreatic NETs.

A large study (770 patients) looking at recurrence risk following resection of lymph node negative pNETs. Overall recurrences in almost 11% of resected patients, but factors such as larger tumors, higher grade, and lymphovascular invasion predicted increased recurrence risk.

3 risk categories (low, moderate, and high risk of recurrence) predicted recurrence -- 2.4%, 9%, and 27.7%. Easy to apply in clinic.

Some info provided on mutations but more data on that are needed.

Excellent work!

https://t.co/wFdM9BysHH